Drug Trial Radar · NCT05477797
Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.
Last checked: Nov 20, 2026Latest source record: Apr 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
420
Planned (sponsor's estimate)
Start
Feb 16, 2023
Primary completion
Jan 15, 2026
Study completion Jan 15, 2026
Sponsor
- Lead sponsor
- RenJi HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 28, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Newly Diagnosed Myeloma Patients, who achieved efficacy above VGPR (very good PR)after initial treatment were enrolled. Patients were then randomly assigned to Id and Rd groups for maintenance treatment. Therapeutic effectiveness will be reviewed monthly until intolerant side effect or disease progression appear . The follow-up period is approximately 2 years.
Conditions
- Progression Free Survival
- Overall Survival
- Maintenance
Interventions
Ixazomib DX/Lenalidomide DXDrug
After assessment of risk stratification,patients will be assigned to Id or Rd group randomly for maintenance therapy. Then they will be reviewed the efficacy monthly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- the percentage of 2 year PFS(progression-free survival)Time frame: from randomization to the end of 2years maintenance.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
shanghai Jiaotong University School of Medicine, Renji Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.